vs
Side-by-side financial comparison of Avidia Bancorp, Inc. (AVBC) and Karyopharm Therapeutics Inc. (KPTI). Click either name above to swap in a different company.
Karyopharm Therapeutics Inc. is the larger business by last-quarter revenue ($34.1M vs $26.8M, roughly 1.3× Avidia Bancorp, Inc.). Avidia Bancorp, Inc. runs the higher net margin — 22.9% vs -299.9%, a 322.8% gap on every dollar of revenue.
Avidia Bank is an American mutual community bank headquartered in Hudson, Massachusetts. It was founded in 2007 when it was formed by a merger between Hudson Savings Bank and Westborough Bank.
AVBC vs KPTI — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $26.8M | $34.1M |
| Net Profit | $5.3M | $-102.2M |
| Gross Margin | — | — |
| Operating Margin | 33.3% | -52.4% |
| Net Margin | 22.9% | -299.9% |
| Revenue YoY | — | 11.6% |
| Net Profit YoY | — | -232.0% |
| EPS (diluted) | — | $-7.02 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $26.8M | $34.1M | ||
| Q3 25 | $28.0M | $44.0M | ||
| Q2 25 | $25.9M | $37.9M | ||
| Q1 25 | $22.9M | $30.0M | ||
| Q4 24 | — | $30.5M | ||
| Q3 24 | — | $38.8M | ||
| Q2 24 | — | $42.8M | ||
| Q1 24 | — | $33.1M |
| Q4 25 | $5.3M | $-102.2M | ||
| Q3 25 | $-907.0K | $-33.1M | ||
| Q2 25 | $3.9M | $-37.3M | ||
| Q1 25 | $-11.6M | $-23.5M | ||
| Q4 24 | — | $-30.8M | ||
| Q3 24 | — | $-32.1M | ||
| Q2 24 | — | $23.8M | ||
| Q1 24 | — | $-37.4M |
| Q4 25 | 33.3% | -52.4% | ||
| Q3 25 | -7.0% | -34.6% | ||
| Q2 25 | 19.4% | -64.3% | ||
| Q1 25 | -72.0% | -110.8% | ||
| Q4 24 | — | -102.4% | ||
| Q3 24 | — | -67.8% | ||
| Q2 24 | — | -65.7% | ||
| Q1 24 | — | -101.9% |
| Q4 25 | 22.9% | -299.9% | ||
| Q3 25 | -3.2% | -75.2% | ||
| Q2 25 | 15.0% | -98.2% | ||
| Q1 25 | -50.5% | -78.2% | ||
| Q4 24 | — | -100.8% | ||
| Q3 24 | — | -82.7% | ||
| Q2 24 | — | 55.6% | ||
| Q1 24 | — | -112.8% |
| Q4 25 | — | $-7.02 | ||
| Q3 25 | $-0.05 | $-3.82 | ||
| Q2 25 | — | $-4.32 | ||
| Q1 25 | — | $-2.77 | ||
| Q4 24 | — | $-2.33 | ||
| Q3 24 | — | $-3.85 | ||
| Q2 24 | — | $-2.97 | ||
| Q1 24 | — | $-4.85 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $275.0M | $60.5M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $379.0M | $-292.9M |
| Total Assets | $2.8B | $108.4M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $275.0M | $60.5M | ||
| Q3 25 | $208.3M | $37.7M | ||
| Q2 25 | $592.5M | $38.7M | ||
| Q1 25 | — | $38.8M | ||
| Q4 24 | — | $62.5M | ||
| Q3 24 | — | $72.8M | ||
| Q2 24 | — | $84.8M | ||
| Q1 24 | — | $30.6M |
| Q4 25 | $379.0M | $-292.9M | ||
| Q3 25 | $372.0M | $-269.3M | ||
| Q2 25 | $191.4M | $-238.9M | ||
| Q1 25 | $186.1M | $-205.9M | ||
| Q4 24 | — | $-186.0M | ||
| Q3 24 | — | $-159.6M | ||
| Q2 24 | — | $-132.1M | ||
| Q1 24 | — | $-169.0M |
| Q4 25 | $2.8B | $108.4M | ||
| Q3 25 | $2.8B | $96.2M | ||
| Q2 25 | $3.0B | $104.9M | ||
| Q1 25 | $2.7B | $127.7M | ||
| Q4 24 | — | $164.4M | ||
| Q3 24 | — | $189.5M | ||
| Q2 24 | — | $214.0M | ||
| Q1 24 | — | $204.5M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $28.4M | $-11.8M |
| Free Cash FlowOCF − Capex | $24.1M | — |
| FCF MarginFCF / Revenue | 89.9% | — |
| Capex IntensityCapex / Revenue | 16.0% | 0.0% |
| Cash ConversionOCF / Net Profit | 5.32× | — |
| TTM Free Cash FlowTrailing 4 quarters | $40.2M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $28.4M | $-11.8M | ||
| Q3 25 | $24.1M | $-5.9M | ||
| Q2 25 | $-2.3M | $-18.7M | ||
| Q1 25 | $-2.2M | $-39.0M | ||
| Q4 24 | — | $-25.8M | ||
| Q3 24 | — | $-19.5M | ||
| Q2 24 | — | $-38.5M | ||
| Q1 24 | — | $-43.7M |
| Q4 25 | $24.1M | — | ||
| Q3 25 | $23.3M | — | ||
| Q2 25 | $-3.3M | — | ||
| Q1 25 | $-3.9M | — | ||
| Q4 24 | — | $-25.9M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | $-43.9M |
| Q4 25 | 89.9% | — | ||
| Q3 25 | 83.2% | — | ||
| Q2 25 | -12.8% | — | ||
| Q1 25 | -16.9% | — | ||
| Q4 24 | — | -84.7% | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | -132.6% |
| Q4 25 | 16.0% | 0.0% | ||
| Q3 25 | 3.1% | 0.0% | ||
| Q2 25 | 3.7% | 0.0% | ||
| Q1 25 | 7.2% | 0.0% | ||
| Q4 24 | — | 0.2% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.6% |
| Q4 25 | 5.32× | — | ||
| Q3 25 | — | — | ||
| Q2 25 | -0.60× | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | -1.62× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
AVBC
Segment breakdown not available.
KPTI
| Products | $32.1M | 94% |
| License And Other | $2.0M | 6% |
